|Bid||168.00 x 200|
|Ask||168.03 x 100|
|Day's Range||167.80 - 171.00|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||15.94|
|Dividend & Yield||4.60 (2.68%)|
|1y Target Est||N/A|
In 2Q17, Amgen’s (AMGN) Enbrel generated revenues of ~$1.5 billion, which represented a ~1% year-over-year decline and a ~24% quarter-over-quarter rise.
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues ...